Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 3;12:781. doi: 10.1038/s41467-021-20980-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Experimental schematic. After a T8 crush injury, wild type (WT) mice received a tail vein injection of AAV2/9-Syn-hM3Dq-mCherry or control virus (AAV2/9-Syn-mCherry) and their locomotion behaviour was measured upon CNO administration every 2 weeks after injury. b BMS scores of injured mice with AAVs expressing hM3Dq-mCherry (left) or control mCherry (right) at indicated time points, before and 1 h after administration of 1 mg/kg CNO. hM3Dq-mCherry group: n = 7; Control group: n = 5. Data shown as mean ± SD (and also for other panels). Factorial Repeated Measures ANOVA with 2 within-subjects factors, followed by two-tailed paired t test at each time point. ns: no statistical difference, **p = 0.0090 (2 weeks); 0.0081 (4 weeks); 0.0012 (8 weeks); 0.0029 (10 weeks), ***p < 0.0001 (6 weeks, 20 weeks). c Stickviews of kinematic hindlimb analysis of intact mouse and mouse with hM3Dq expression before and after CNO injection (1 mg/kg) at 4 weeks after injury. The phases of dragging, stance, or swing were marked in indicated colours. Cycle duration (d) and swing/stance ratio (e) of intact mice and spinal cord injured mice with hM3Dq expression. Injured mice expressing hM3Dq dragged before CNO treatment, but had similar stance/swing phase distributions as intact mice (Bar chart) after CNO treatment. Two tailed paired t test for within-group comparison (#) and Wilcoxon rank sum for between-group comparison (*). **p = 0.0022 (hM3Dq); 0.0043 (hM3Dq CNO) and ^###p < 0.001. Quantification of the maximum iliac crest heights (f) and the maximum toe heights (g). One-Way ANOVA with Tukey’s post test for between-group (*) and two tailed paired t tests for within-group (#) comparsion. ***p < 0.001; **p = 0.0039; ^##p = 0.0040 (f); ***p < 0.001; ^#p = 0.0166. For (d)–(g), n = 6 for each group.